Plectonic Biotech

Executive Summary

Plectonic Biotech, headquartered in Munich, Germany, was founded in 2018 to pioneer targeted therapeutics using its proprietary Logibody platform based on DNA nanotechnology. The company aims to develop highly specific molecular therapies that redefine precision medicine. Although the company remains in early preclinical stages with no disclosed pipeline or funding rounds, its innovative approach positions it within the competitive fields of drug delivery and synthetic biology. The limited public information suggests a need for near-term validation through financing or preclinical data.

Upcoming Catalysts (preview)

• 2026Series A financing round50% success
• 2027First in vivo proof-of-concept data30% success
• TBDStrategic partnership with pharma20% success